Prediction of effectiveness of potassium-competitive acid blocker and serotonin noradrenaline reuptake inhibitor on abnormal sensation in the throat: use of patient-reported outcome measures (PROMs)
Sign Up to like & getrecommendations! Published in 2021 at "European Archives of Oto-Rhino-Laryngology"
DOI: 10.1007/s00405-020-06544-0
Abstract: Purpose To determine patients with abnormal sensation in the throat (AST) who would respond to potassium-competitive acid blocker (P-CAB) or serotonin noradrenaline reuptake inhibitor (SNRI) treatment. Methods AST patients were randomly divided into two groups.… read more here.
Keywords: potassium competitive; treatment; throat; sensation throat ... See more keywords
Vonoprazan: A New Potassium-Competitive Acid Blocker
Sign Up to like & getrecommendations! Published in 2023 at "Journal of Pharmacy Technology"
DOI: 10.1177/87551225231166531
Abstract: Objective: To review the safety, efficacy, and tolerability of vonoprazan for the treatment of Helicobacter pylori infection in adults. Data Sources: A literature search was performed through PubMed using the following key terms: vonoprazan, Voquezna,… read more here.
Keywords: acid; competitive acid; acid blocker; potassium competitive ... See more keywords
Novel Potassium-Competitive Acid Blocker, Tegoprazan, Protects Against Colitis by Improving Gut Barrier Function
Sign Up to like & getrecommendations! Published in 2022 at "Frontiers in Immunology"
DOI: 10.3389/fimmu.2022.870817
Abstract: Inflammatory bowel disease (IBD) is a chronic immune-mediated disorder characterized by prolonged inflammation of the gastrointestinal tract. IBD can result from gut barrier dysfunction, altered gut microbiota, and abnormal intestinal immunity induced by environmental factors… read more here.
Keywords: acid blocker; tegoprazan; acid; competitive acid ... See more keywords
Pharmacodynamic and Pharmacokinetic Drug Interactions between Fexuprazan, a Novel Potassium-Competitive Inhibitor, and Aspirin, in Healthy Subjects
Sign Up to like & getrecommendations! Published in 2023 at "Pharmaceutics"
DOI: 10.3390/pharmaceutics15020549
Abstract: Acid-reducing agents are commonly used for the prevention of aspirin-induced gastrointestinal complications such as peptic ulcers. As a novel potassium-competitive acid blocker, fexuprazan is expected to prevent aspirin-induced gastrointestinal complications. This randomized, open-label study aimed… read more here.
Keywords: fexuprazan; aspirin induced; pharmacodynamic pharmacokinetic; novel potassium ... See more keywords
Is a Potassium-Competitive Acid Blocker Truly Superior to Proton Pump Inhibitors in Terms of Helicobacter pylori Eradication?
Sign Up to like & getrecommendations! Published in 2021 at "Gut and liver"
DOI: 10.5009/gnl20242
Abstract: Vonoprazan (VPZ), a new potassium-competitive acid blocker, has been approved and used for Helicobacter pylori eradication in Japan. To date, many studies, as well as several systematic reviews and meta-analyses (MAs), have compared VPZ-based 7-day… read more here.
Keywords: competitive acid; based triple; potassium competitive; triple therapy ... See more keywords